Opinion|Videos|May 1, 2026
Managing Fatigue with ARPIs in Metastatic Castration-Sensitive Prostate Cancer in the Clinic
This series explores how fatigue and other treatment-related adverse events influence quality of life and treatment persistence in metastatic castration-sensitive prostate cancer, with a focus on practical strategies for assessment, management, and supportive care in patients receiving ADT and ARPI-based therapy.
Episodes in this series
This series explores how fatigue and other treatment-related adverse events influence quality of life and treatment persistence in metastatic castration-sensitive prostate cancer, with a focus on practical strategies for assessment, management, and supportive care in patients receiving ADT and ARPI-based therapy.
Related to this article
Patient goals, disease features, and response to prior therapy guide treatment choices across high-risk NMIBC, according to Suzanne B. Merrill, MD, FACS.
Suzanne B. Merrill, MD, discusses emerging perioperative approaches in MIBC and the potential for more personalized treatment selection based on disease characteristics.
BCG monotherapy and a high-quality TURBT remain the foundation for BCG-naive high-risk NMIBC, according to Vignesh T. Packiam, MD.
Independent urology practices head into 2027 facing a conversion factor cut, prior authorization hurdles, and Part B drug price negotiation, according to Gary Kirsh, MD.
Updated CAPItello-281 data support capivasertib plus abiraterone in PTEN-deficient mHSPC, according to Daniel J. George, MD.
Benjamin Garmezy, MD, discusses personalizing mHSPC treatment intensification based on disease burden, molecular biomarkers, and patient-specific factors.
Patient priorities and practice logistics should guide therapy selection in BCG-unresponsive NMIBC, according to Katie S. Murray, DO, MS, FACS.
Biomarkers including HRR mutations, PTEN loss, and PSMA expression can guide triplet selection in mHSPC, according to Benjamin Garmezy, MD.
Trending on Urology Times
1
PTEN loss: From biomarker to treatment strategy in mHSPC
2
Q&A: Gary Kirsh, MD, on health policy for independent urology
3
Modern BCG outperforms historic benchmarks in high-risk NMIBC
4
Q&A: Suzanne B. Merrill, MD, FACS, on treating high-risk NMIBC
5